DIRS.INFO The most relevant business & tech news

☆ Ozempic Is Repairing a Hole in Our Diets Created by Processed Foods - The New York Times
▼ + stars: | 2024-05-07 | by ( Johann Hari | ) www.nytimes.com time to read: +1 min

So when I shrank from 203 pounds to 161 in a year, I was baffled by my feelings. I was taking Ozempic, and I was haunted by the sense that I was cheating and doing something immoral. But the fact that so many of us are turning to the new weight-loss drugs can be an opportunity to find a way out of that trap of shame and stigma — and to a more truthful story. I was born in 1979, and by the time I was 21, obesity rates in the United States had more than doubled. And how do these new weight-loss drugs work?

Persons: I’m, It’s Locations: United States

☆ A woman who lost 55 pounds by making 2 simple changes shared 10 fat loss lessons she learned
▼ + stars: | 2024-05-06 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +7 min

This time, she wanted to get healthier and lose weight in a way that was sustainable. Tjelle's experience is a reflection of how approaches and attitudes toward weight loss are changing. Tjelle, now 30, shared the 10 fat loss and fitness lessons she's learned during her journey. Walking is great for fat loss"Walking was by far the most effective exercise for weight loss early in my weight loss journey," Tjelle said. You won't always feel motivatedFor the first few months of her weight loss journey, Tjelle really didn't want to go to the gym, she said.

Persons: —, Megan, Tjelle, she's, Megan Tjelle, Patience Organizations: Service, Business, Research Locations: Chicago, Seattle Sutton

☆ Jeff Bezos, Doja Cat and Pamela Anderson Pregame the Met Gala
▼ + stars: | 2024-05-06 | by ( Callie Holtermann | ) www.nytimes.com time to read: +1 min

On Sunday evening, the rapper Doja Cat swept into an upscale French restaurant in SoHo carrying a disposable Starbucks cup. She stashed it at the bar, and then made her way to the rear of the room to kiss the actress Pamela Anderson on one makeup-free cheek. Ms. Anderson was hosting a party with the label Monse as a kind of amuse-bouche for the Met Gala the next night. “I’m going to be walking all of those scary feelings out,” she said. Guests sipping Sancerre traded thoughts on increasingly elaborate gala prep routines.

Persons: Pamela Anderson, Anderson, Ms, “ I’m, ”, radishes, sipping Sancerre Locations: SoHo, La

☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
▼ + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.

Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S

☆ Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
▼ + stars: | 2024-05-03 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Read previewDanish drugmaker Novo Nordisk will lower prices of its weight loss drug Wegovy as it plans to raise sales volumes and navigate tough competition. Prices for the blockbuster drug fell in the first quarter. Sales of Wegovy more than doubled in the first quarter year-on-year, to 9.4 billion Danish crowns, or $1.3 billion, according to the company's earnings. They did not specify how much Novo plans to cut Wegovy's prices. AdvertisementThe Danish pharmaceutical maker, which also produces viral weight loss drug Ozempic, reported better-than-expected sales of 65 billion Danish crowns, or $9.4 billion, in the first quarter.

Persons: —, Karsten Munk Knudsen, Knudsen, Lars Fruergaard Jorgensen, Ozempic, Eli Lilly, Wegovy, Bernie Sanders, Goldman Sachs, Oprah Winfrey, Elon Musk, Charles Barkley Organizations: Service, Nordisk, Business Locations: Danish, Novo

☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
▼ + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.

Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America

☆ Wegovy maker Novo Nordisk down 4%, heads for worst day since October
▼ + stars: | 2024-05-03 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% loss on Thursday as analysts pored over the details of the firm's first-quarter results and monitored a potential rival weight loss treatment. The company reported that sales for its blockbuster injectable weight loss treatment Wegovy, more than doubled to 9.38 billion Danish kroner ($1.4 billion). Novo Nordisk, which also makes diabetes treatment Ozempic, said the rise in sales had offset a slight reduction in prices. Analysts expected even higher weight loss drug sales in the quarter, and some noted that Novo Nordisk's 2024 outlook raise for both sales growth and operating profit was due to one-off accounting adjustments. The boom in demand for weight loss treatments saw Novo Nordisk overtake French luxury group LVMH to become Europe's most valuable company last year.

Persons: Karsten Knudsen, Karen Andersen Organizations: Novo Nordisk, Novo, Morningstar Locations: Novo

☆ Woman Who Sold Misbranded Ozempic on TikTok Faces Smuggling Charge
▼ + stars: | 2024-05-02 | by ( Matthew Mpoke Bigg | More About Matthew Mpoke Bigg | ) www.nytimes.com time to read: +1 min

A woman in New York who was using TikTok to sell unauthorized weight-loss drugs, including products labeled Ozempic, is facing charges of smuggling and receiving and distributing misbranded drugs, federal prosecutors said. The arrest on Wednesday of Isis Navarro Reyes, 36, who also went by Beraly Navarro and, according to prosecutors, was not licensed to administer medication, followed an investigation that involved an undercover officer. Late last year, the officer sent a message to a cellphone number listed by her at the end of a TikTok video. In the video, Ms. Reyes, of Shirley, N.Y., on Long Island, showed her viewers how to inject what she claimed was Ozempic and shared her experience using the drug. In January, after exchanging messages with Ms. Reyes, the officer asked to buy some Ozempic, a drug for diabetes that has become popular for weight loss.

Persons: Isis Navarro Reyes, Beraly Navarro, Reyes Organizations: Southern, of Locations: New York, Shirley, N.Y, Long, of New York

☆ A millennial couldn't afford the Mounjaro weight-loss drug so he started secretly working 2 remote jobs. He's on track to make $166,000 this year and says he's lost 45 pounds.
▼ + stars: | 2024-05-01 | by ( Jacob Zinkula | ) www.businessinsider.com time to read: +6 min

A millennial in California is secretly working a second remote job so he can afford weight-loss drugs. AdvertisementLast August, George decided he wanted to try to work a second remote job — and not tell his employers he was job juggling. He was able to afford Mounjaro and said he's dropped 45 pounds — from 220 lbs to 175 lbs — since he started taking it in October. AdvertisementAfter a roughly monthlong search, he started his second job and was able to afford Mounjaro. Are you working multiple remote jobs at the same time and willing to discuss details about your pay and schedule?

Persons: Zepbound, —, George, Eli Lilly, he's, George hasn't, it's Organizations: Service, FDA, Nordisk's Ozempic, Business Locations: California, Mounjaro

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ Barbra Streisand asked Melissa McCarthy whether she used Ozempic, sparking a backlash from fans
▼ + stars: | 2024-04-30 | by ( Eammon Jacobs | ) www.businessinsider.com time to read: +3 min

Barbra Streisand asked Melissa McCarthy on Instagram whether she used Ozempic. Stars including Amy Schumer and Chelsea Handler have been open about using the buzzy weight loss drug. AdvertisementBarbra Streisand asked Melissa McCarthy if she used Ozempic to lose weight on Instagram, sparking a backlash from fans. While many fans praised the pastel green outfit McCarthy wore at the event, Streisand made a surprising remark about her weight loss. Celebrities including Elon Musk, Amy Schumer, and Chelsea Handler have all been open about using such weight loss drugs to slim down.

Persons: Barbra Streisand, Melissa McCarthy, Amy Schumer, Chelsea Handler, —, McCarthy, Adam Shankman, Matthew Bourne, Streisand, ”, b0eNUtm7xK, Barbara, Ozempic, Elon Musk, Jimmy Kimmel's, wasn't Organizations: Service, Center Theatre, Business, Celebrities, Hollywood Locations: Los Angeles

☆ Barbra Streisand ‘forgot the world is reading’ when she asked Melissa McCarthy if she took Ozempic on Instagram
▼ + stars: | 2024-04-30 | by ( Alli Rosenbloom | ) edition.cnn.com time to read: +1 min

CNN —Barbra Streisand is addressing a divisive comment she wrote under a photo that actor Melissa McCarthy posted on her Instagram page on Monday. In the comment, Streisand asked McCarthy if she took Ozempic – a popular weight loss medication, among its other functions – spurring backlash online. “Below them was a photo of my friend Melissa McCarthy who I sang with on my Encore album,” she wrote. I forgot the world is reading!”CNN has reached out to representatives for McCarthy and Streisand for comment. Ozempic is a brand name for the generic drug semaglutide, and is approved by the US Food and Drug Administration to treat diabetes.

Persons: Barbra Streisand, Melissa McCarthy, Streisand, McCarthy, Ozempic, she’d, ”, “, Adam Shankman Organizations: CNN, Center, US Food and Drug Administration

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

☆ GNC is redesigning stores to draw people taking Ozempic
▼ + stars: | 2024-04-29 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +3 min

The brand hopes a new strategy tailored to people taking GLP-1 drugs for weight loss will help draw customers into stores and grow its business. We can help,” advertises an overhead banner in GNC’s new GLP-1 “support section.”GNC's new GLP-1 support section is available in all 2,300 stores across the United States. JON SIMON/GNCDanish pharmaceutical company Novo Nordisk is reaping huge profits from creating and selling the hit GLP-1 products. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. GNC, which filed for bankruptcy in 2020 and closed more than 1,200 stores, is the latest brand to build a strategy around people taking GLP-1s.

Persons: New York CNN — GNC, GNC, ”, JON SIMON, WeightWatchers Organizations: New, New York CNN, Novo Nordisk, Pfizer, Roche, JPMorgan, Equinox Locations: New York, United States, Danish

☆ How Supplement Stores Are Trying to Tap Into the Ozempic Boom
▼ + stars: | 2024-04-29 | by ( Jordyn Holman | ) www.nytimes.com time to read: 1 min

As diabetes and weight-loss drugs like Ozempic and Wegovy took off in the last few years, many people turned away from established diet and nutrition products. Now, two retailers that specialize in nutritional supplements — GNC and the Vitamin Shoppe — are trying new approaches to win over people who are taking those drugs or who are interested in them. GNC is dedicating a wall of supplements in its more than 2,300 stores to products that it believes will appeal to people on Ozempic, which contains the compound semaglutide, and other drugs that are known as GLP-1 medicines. The chain is also training workers to help customers assess which substances could help them manage common side effects of those prescription drugs. Michael Costello, chief executive of GNC, said his company saw a “big opening” in helping individuals taking such drugs for weight loss.

Persons: Wegovy, Michael Costello

☆ 'Ozempic face' could create a huge market for fillers. One newly-public company wants to cash in.
▼ + stars: | 2024-04-25 | by ( Geoff Weiss | Julia Pugachevsky | ) www.businessinsider.com time to read: +1 min

Its CEO told Bloomberg that weight-loss drugs could boost its fillers business. Ozempic face is a result of aging and rapid weight loss, one cosmetic dermatologist said. NEW LOOK Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. AdvertisementThe CEO of Swiss pharmaceutical giant Galderma thinks the popularity of weight-loss drugs like Ozempic could boost its facial fillers business. That's because Ozempic can result in a sunken-in look in some patients' faces, Galderma CEO Flemming Ornskov told Bloomberg — an effect he said fillers can help counteract.

Persons: —, Flemming Ornskov, Flemming Organizations: Swiss pharma, Bloomberg, Service, Business Locations: Swiss

☆ More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says
▼ + stars: | 2024-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But some eligible beneficiaries could still face out-of-pocket costs for the highly popular and expensive drug, KFF said. Certain Medicare prescription drug plans may also wait until 2025 to cover Wegovy. Medicare's budget could be strained as more plans cover the costs of Wegovy. Among the Medicare beneficiaries who are obese or overweight and have a history of heart disease, 1.9 million also have diabetes, according to KFF. That makes them already eligible for Medicare coverage of other GLP-1 drugs approved for that condition.

Persons: KFF Organizations: Novo Nordisk, Medicare, Drug Administration, Novo Locations: London, Britain, U.S

☆ Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
▼ + stars: | 2024-04-24 | by ( Ryan Anastasio | ) www.cnbc.com time to read: +2 min

The U.S. Senate has launched an investigation into the high price of Novo Nordisk 's popular weight loss and diabetes drugs Ozempic and Wegovy in the United States. "As important as these drugs are, they will not do any good for the millions of patients who cannot afford them," wrote Sanders. Wegovy, which is even more expensive than Ozempic, is subject to similarly disparate pricing overseas, wrote Sanders. The powerful progressive senator also made a simple request of the drug company CEO: "Will Novo Nordisk substantially reduce both the list price and the net price of both Ozempic and Wegovy?" He gave Novo Nordisk until May 8 to answer a series of questions about the drug's pricing.

Persons: Ozempic, Danish drugmaker, Sen, Bernie Sanders, Sanders, Lars Fruergaard Jørgensen, Jørgensen Organizations: U.S . Senate, Novo Nordisk, Vermont Independent, Health, Education, Labor, Pensions, Nordisk Locations: United States, Danish, Vermont, Canada, Germany

☆ Ozempic and Wegovy Have Health Benefits Beyond Weight Loss - The New York Times
▼ + stars: | 2024-04-24 | by ( David Wallace-Wells | ) www.nytimes.com time to read: +3 min

Last year was called the year of Ozempic, though it was also a year of Ozempic backlash and Ozempic shortages, which could persist for years. Even so, we appear very far from a peak for GLP-1 drugs, like Ozempic and Wegovy, which are powered by a molecule called semaglutide, and Mounjaro, which uses its cousin tirzepatide. It seems possible to imagine a future in which almost everyone is taking some variety of GLP-1 drug, and with a pretty good reason to do so. Patients on Ozempic and Wegovy can lose 15 to 20 percent or more of their weight in a little over a year, and if they stay on the drugs, the weight tends to stay off. Semaglutide has been shown to eliminate or reduce the need for insulin among those with recent-onset Type 1 diabetes.

Persons: tirzepatide, Wegovy, we’ve, Semaglutide Locations: Alzheimer’s

☆ A woman who lost 105 pounds shares two things that made eating healthy and exercising regularly easier
▼ + stars: | 2024-04-22 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +10 min

Megan Tjelle lost 55 pounds by walking and eating healthy in a calorie deficit. Tjelle had started a demanding career, and working night shifts as a nurse made it hard to develop healthy eating and exercise habits. Her plantar fasciitis, which she initially put down to her work, eased when she lost weight. As Tjelle lost weight, she gained confidence and could feel herself getting fitter as she was able to exercise more. AdvertisementAlthough her appetite dropped, she continued eating healthy meals and ensured she was consuming enough protein to help her hold on to muscle while losing fat.

Persons: Megan Tjelle, Tjelle, Wegovy, —, overeating, she'd, She'd, Megan Tjelle Tjelle, I've Organizations: Service, Research, FDA, Seattle Sutton, GPL Locations: Chicago, Seattle, Wegovy

☆ Ozempic influencers are angry after TikTok's crackdown on weight loss content
▼ + stars: | 2024-04-22 | by ( Jordan Hart | ) www.businessinsider.com time to read: +1 min

The video platform is cracking down on weight loss-related content in a new set of guidelines. The changes will restrict or outright ban certain types of weight loss videos. AdvertisementTikTok is phasing out weight loss content, and thousands of creators will have to find a new niche to post about. The new guidelines, which will go into effect on May 17, prohibit content centered on "extreme" diets, the misuse of medications for weight loss, and more. Creators who post about restrictive diets, "using medication or supplements for weight loss or muscle gain," or promoting weight loss products will find the content restricted to users 18 years and older, according to the guidelines.

Persons: — Organizations: Service, Business

☆ Let Them Eat … Everything
▼ + stars: | 2024-04-21 | by ( Lisa Miller | ) www.nytimes.com time to read: +1 min

The sheet-pan chicken and roasted broccoli are out of the oven, and white rice is steaming on the stove. Sole-Smith tries not to be a short-order cook. “Respect the labor,” is how she puts it, reminding her children that if they don’t like what she has prepared, there’s other stuff to eat in the house. A pullout shelf in the pantry holds Tate’s chocolate chip cookies, Goldfish crackers, pea snaps, and chocolate kisses. A year ago, Sole-Smith published “Fat Talk: Parenting in the Age of Diet Culture,” a guide to helping parents grapple with their discomfort and anxiety about weight and food.

Persons: Smith, Violet, Beatrix, Penelope Organizations: Virginia Locations: Cold, N.Y

Lars Fruergaard Jorgensen has a problem: Too many people want what he’s selling. Even if the company isn’t quite a household name, the TV jingle for its best-selling drug — “Oh-oh-ohhh, Ozempic!” — might ring in your ears. Across the United States, Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status and helped make the company Europe’s most valuable public firm. Last year, when the company was celebrating its centenary, Novo Nordisk’s revenue jumped by a third, to 232 billion Danish kroner, or $33 billion. “Nobody forecast a 100-year-old company would grow more than 30 percent,” he said, seemingly torn between pride and amazement.

Persons: Lars Fruergaard Jorgensen, Jorgensen, ” Mr, ”, Wegovy Organizations: Novo Nordisk, Novo Nordisk’s, Nordisk Locations: Danish, United States, Copenhagen

☆ How Ozempic Is Transforming a Small Danish Town
▼ + stars: | 2024-04-20 | by ( Eshe Nelson | ) www.nytimes.com time to read: +1 min

As the sun sets over the harbor in Kalundborg, a small town about 60 miles west of Copenhagen, light streams through the glass walls of Shaun Gamble’s cafe and bathes his afternoon customers in a warm glow. Nearby, at a sprawling manufacturing plant, Novo Nordisk makes nearly all of its semaglutide, the active ingredient in the company’s wildly popular diabetes and obesity treatments Ozempic and Wegovy. It’s the largest manufacturing investment in Denmark by a company, and it’s happening in this town of fewer than 17,000 people. Novo Nordisk plans to add 1,250 jobs to the existing 4,500 employees at the Kalundborg plant. A highway is being extended; investors are snapping up houses and planning new construction; universities have begun offering biotech courses to feed Novo Nordisk and nearby businesses with workers.

Persons: Shaun Gamble’s Organizations: Novo Nordisk, Nordisk Locations: Kalundborg, Copenhagen, Denmark, Novo

☆ Most people on weight loss drugs are spending less on restaurants and takeout, survey says
▼ + stars: | 2024-04-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Most people taking those medications, called GLP-1s, say they are spending less on eating out at restaurants and ordering takeout, according to a Morgan Stanley survey released on Tuesday. GLP-1s include Novo Nordisk 's blockbuster weight loss injection Wegovy and diabetes counterpart Ozempic, along with Eli Lilly 's popular weight loss treatment Zepbound and diabetes injection Mounjaro. "There is growing evidence that the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants," Morgan Stanley analysts said in the survey. Those people are "early in their weight loss journey," but are making substantial changes to their diets and spending, according to the firm. Roughly half of people reported cutting consumption of regular sodas, alcohol and salty snacks by 50% or more since starting on weight loss drugs.

Persons: —, Morgan Stanley, Eli Lilly, Hollie Adams, Reuters Morgan Stanley, Morgan Stanley survery Organizations: Washington Post, Novo Nordisk, Reuters, Consumers Locations: Manhattan, London, Britain

Search resuls for: "Ozempic"

25 mentions found